Remove 2002 Remove Clinical Trials Remove Conditions Remove Epilepsy
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Refractory paediatric epilepsy. Spasticity from neurological conditions.

article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

THC 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Green Relief - Untitled Article

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.